Biomarker prediction of efficacy to vandetanib plus gemcitabine in a phase II double blind multicenter randomized placebo controlled trial in locally advanced or metastatic pancreatic carcinoma.
Authors: Neoptolemos, J.P., Hickish, T. et al.
Journal: JOURNAL OF CLINICAL ONCOLOGY
Volume: 35
eISSN: 1527-7755
ISSN: 0732-183X
DOI: 10.1200/JCO.2017.35.15_suppl.4104
Source: Web of Science (Lite)